Label: AK-CON- naphazoline hydrochloride solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 30, 2011

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Sterile

  • DESCRIPTION

    Naphazoline hydrochloride, an ocular vasoconstrictor, is an imidazoline derivative sympathomimetic amine. It occurs as a white, odorless crystalline powder having a bitter taste and is freely soluble in water and in alcohol. The active ingredient is represented by the structural formula:

    Chemical Structure

    Chemical Name:

    2-(1-Naphthylmethyl)-2-imidazoline monohydrochloride

    Contains:

    Active: naphazoline HCl 1 mg (0.1%). Preservative: benzalkonium chloride 0.1mg (0.01%).
    Inactives: Boric acid; edetate disodium; purified water; sodium chloride; sodium carbonate; and hydrochloric acid may be added to adjust the pH (5.5 to 7.0).

  • CLINICAL PHARMACOLOGY

    Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation of the drug upon the alpha-adrenergic receptors in the arterioles of the conjunctiva, resulting in decreased conjunctival congestion. Naphazoline belongs to the imidazoline class of sympathomimetics.

  • INDICATIONS AND USAGE

    Naphazoline Hydrochloride Ophthalmic Solution is indicated for use as a topical ocular vasoconstrictor.

  • CONTRAINDICATIONS

    Contraindicated in the presence of an anatomically narrow angle or in narrow-angle glaucoma or in persons who have shown hypersensitivity to any component of this preparation.

  • WARNINGS

    Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. Use in children, especially infants, may result in CNS depression leading to coma and marked reduction in body temperature.

  • PRECAUTIONS

    General:

    For topical ophthalmic use only. Use with caution in the presence of hypertension, cardiovascular abnormalities, hyperglycemia (diabetes), hyperthyroidism, infection or injury.

    Patient Information:

    Patients should be advised to discontinue the drug and consult a physician if relief is not obtained within 48 hours of therapy, if irritation, blurring or redness persists or increases, or if symptoms of systemic absorption occur, i.e., dizziness, headache, nausea, decrease in body temperature, or drowsiness.

    To prevent contaminating the dropper tip and solution, do not touch the eyelids or the surrounding area with the dropper tip of the bottle. If solution changes color or becomes cloudy, do not use.

    Drug Interactions:

    Concurrent use of maprotiline or tricyclic antidepressants and naphazoline may potentiate the pressor effect of naphazoline. Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. (See WARNINGS.)

    Pregnancy:

    Pregnancy Category C: Animal reproduction studies have not been
    conducted with naphazoline. It is also not known whether naphazoline can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naphazoline should be given to a pregnant woman only if clearly needed.

    Nursing Mothers:

    It is not known whether naphazoline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naphazoline is administered to a nursing woman.

    Pediatric Use:

    Safety and effectiveness in pediatric patients have not been established. See “WARNINGS.” and “CONTRAINDICATIONS.

  • ADVERSE REACTIONS

    Ocular: Mydriasis, increased redness, irritation, discomfort, blurring, punctate keratitis, lacrimation, increased intraocular pressure.

    Systemic: Dizziness, headache, nausea, sweating , nervousness, drowsiness, weakness, hypertension, cardiac irregularities, and hyperglycemia.

  • DOSAGE AND ADMINISTRATION

    Instill one or two drops in the conjunctival sac(s) every three to four hours as needed.

  • HOW SUPPLIED

    Naphazoline Hydrochloride Ophthalmic Solution, USP) is supplied as a sterile 0.1% solution in

          15 mL plastic dropper bottles. NDC 17478-216-12

    Storage: Store at 20° to 25°C (68° to 77°F). Keep container tightly closed.

    Rx Only

    Manufactured by:

    Akorn Inc.
    Lake Forest, IL 60045

    Repackaged by:

    Rebel Distributors Corp

    Thousand Oaks, CA 91320

  • Principal Display Panel

    AK-Con 0.1%

  • INGREDIENTS AND APPEARANCE
    AK-CON 
    naphazoline hydrochloride solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:21695-915(NDC:17478-216)
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    naphazoline hydrochloride (UNII: MZ1131787D) (naphazoline - UNII:H231GF11BV) naphazoline hydrochloride1 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    edetate disodium (UNII: 7FLD91C86K)  
    water (UNII: 059QF0KO0R)  
    sodium chloride (UNII: 451W47IQ8X)  
    SODIUM CARBONATE (UNII: 45P3261C7T)  
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    BORIC ACID (UNII: R57ZHV85D4)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:21695-915-1515 mL in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA08359008/22/1974
    Labeler - Rebel Distributors Corp. (118802834)
    Establishment
    NameAddressID/FEIBusiness Operations
    Rebel Distributors Corp.118802834RELABEL, REPACK